139 related articles for article (PubMed ID: 16217588)
21. The effect of raloxifene treatment in postmenopausal women with CKD.
Ishani A; Blackwell T; Jamal SA; Cummings SR; Ensrud KE;
J Am Soc Nephrol; 2008 Jul; 19(7):1430-8. PubMed ID: 18400939
[TBL] [Abstract][Full Text] [Related]
22. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures.
Oleksik AM; Ewing S; Shen W; van Schoor NM; Lips P
Osteoporos Int; 2005 Aug; 16(8):861-70. PubMed ID: 15558238
[TBL] [Abstract][Full Text] [Related]
23. Benefits and risks of raloxifene by vertebral fracture status.
Sontag A; Wan X; Krege JH
Curr Med Res Opin; 2010 Jan; 26(1):71-6. PubMed ID: 19908937
[TBL] [Abstract][Full Text] [Related]
24. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
Borgström F; Johnell O; Kanis JA; Oden A; Sykes D; Jönsson B
Pharmacoeconomics; 2004; 22(17):1153-65. PubMed ID: 15612833
[TBL] [Abstract][Full Text] [Related]
26. Skeletal and nonskeletal effects of raloxifene.
Gluck O; Maricic M
Curr Osteoporos Rep; 2003 Dec; 1(3):123-8. PubMed ID: 16036075
[TBL] [Abstract][Full Text] [Related]
27. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
28. Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis.
Brandi ML
Clin Exp Rheumatol; 2000; 18(3):309-10. PubMed ID: 10895366
[No Abstract] [Full Text] [Related]
29. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
30. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
31. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.
Uusi-Rasi K; Beck TJ; Semanick LM; Daphtary MM; Crans GG; Desaiah D; Harper KD
Osteoporos Int; 2006; 17(4):575-86. PubMed ID: 16392026
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
34. Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis.
Nakamura T; Liu JL; Morii H; Huang QR; Zhu HM; Qu Y; Hamaya E; Thiebaud D
J Bone Miner Metab; 2006; 24(5):414-8. PubMed ID: 16937275
[TBL] [Abstract][Full Text] [Related]
35. The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis.
Beekman KM; Veldhuis-Vlug AG; den Heijer M; Maas M; Oleksik AM; Tanck MW; Ott SM; van 't Hof RJ; Lips P; Bisschop PH; Bravenboer N
Bone; 2019 Jan; 118():62-68. PubMed ID: 29032175
[TBL] [Abstract][Full Text] [Related]
36. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
37. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.
Bjarnason NH; Sarkar S; Duong T; Mitlak B; Delmas PD; Christiansen C
Osteoporos Int; 2001; 12(11):922-30. PubMed ID: 11808544
[TBL] [Abstract][Full Text] [Related]
38. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
[TBL] [Abstract][Full Text] [Related]
39. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.
Kanis JA; Borgström F; Johnell O; Oden A; Sykes D; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):15-25. PubMed ID: 15672210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
